Navigation Links
Clostridium difficile Infection: Current Challenges and Controversies
Date:1/20/2009

Complimentary Continuing Education Virtual Lecture and Podcast for Healthcare Professionals

VOORHEES, N.J., Jan. 20 /PRNewswire/ -- Current education about Clostridium difficile infection (CDI) is critical for several reasons. The epidemiology of CDI is changing and has been marked by increasing rates and more severe disease. In addition, the epidemic strain continues to be reported in an expanding list of states across the United States and worldwide.

To address the need for current education on CDI risk factors, diagnostic techniques, and optimal treatment strategies, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education virtual lecture and podcast for physicians, pharmacists, and nurses titled Clostridium difficile Infection: Current Challenges and Controversies. This activity is supported by an educational grant from ViroPharma Incorporated.

The information contained in this virtual lecture and podcast was originally presented as a live symposium during the 2008 ICAAC/IDSA Joint Meeting. The chairperson for this program is international expert in infectious diseases, Dale N. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Associate Chief of Staff for Research and Development at Hines Veterans Affairs Hospital in Hines, Illinois. Other faculty include experts in infectious diseases, gastroenterology, and infection control from leading medical institutions across the United States.

Healthcare professionals can visit www.rmei.com/CDI052 to access this virtual lecture and podcast.

"Robert Michael Educational Institute LLC recognizes that continuing education plays a crucial role in the provision of quality healthcare and is dedicated to offering professionals meaningful opportunities for lifelong learning," says President and CEO, Robert M. Colleluori.

RMEI is a medical education company that specializes in independent, accredited, and nonaccredited education. The goal of all accredited RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit www.rmei.com.


'/>"/>
SOURCE Robert Michael Educational Institute LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
2. Putting a new spin on current research
3. New small-scale generator produces alternating current by stretching zinc oxide wires
4. Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
5. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
6. 72% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds
7. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
8. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
9. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
10. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):